Acepodia is a clinical-stage biotechnology company developing innovative and highly effective cell therapies for cancer that are broadly accessible for patients.
Leveraging its Antibody-Cell Conjugation (ACC) technology, the company links tumor-targeting antibodies to its proprietary immune effector cells, such as gamma delta T cells and natural killer (NK) cells to create novel antibody cell effector (ACE) therapies, which have increased binding strength against tumors that express low levels of tumor antigens.
Acepodia is made up of seasoned leadership and scientific experts dedicated to advancing its robust pipeline of off-the-shelf ACE therapies with the potential to bring powerful, accessible cell therapies to a broad population of patients across a variety of solid tumors and hematologic cancers.
Company Details
- Employees
- 53
- Founded
- -
- Address
- 1600 Harbor Bay Pkwy, Suite 140,taiwan, Province Of China
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- acepodia.com
- Keywords
- Oncology, Cancer Cell Immunotherapy, Allogeneic, Off-the-Shelf, NK Cells, Biotechnology, Interdisciplinary Technology, CAR, Cell Therapy.
- HQ
- Alameda, California
Acepodia Questions
Acepodia's website is acepodia.com
Acepodia's LinkedIn profile is https://tw.linkedin.com/company/acepodia
Acepodia has
53 employees.
View email and phone details for 53
employees at Acepodia.
Acepodia's industry is
Biotechnology Research
Acepodia's top competitors are
Cabaletta Bio,
Adicet Bio, Inc,
Sastra Cell Therapy,
Arcellx,
Arsenal Biosciences, Inc.,
Kyverna Therapeutics,
Epimab Biotherapeutics, Inc.,
Actitrexx Gmbh,
Steminent Biotherapeutics,
Bioheng Therapeutics.
Acepodia's categories are Biotechnology Research
Acepodia's founding year is 2016
